Dr. Michael C. Chappell, MD
Ophthalmology (Ophthalmic Plastic and Reconstructive Surgery Physician)
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 536
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2007Medical school: University of Arkansas College of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmic Plastic and Reconstructive Surgery Physician primary
AR license E8117
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Lukes Hospital of Kansas City Kansas City, MO
Medical groups
- Moyes Eye Center, P.c. (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 536
- Services billed
- 3,238
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Photography of content of eyes | 552 | 458 |
| Exam of visual field with limited testing | 214 | 211 |
| Established patient problem focused exam of visual system | 181 | 163 |
| Removal of excessive skin and fat of upper eyelid | 161 | 161 |
| New patient office or other outpatient visit, 45-59 minutes | 161 | 161 |
| Established patient office or other outpatient visit, 10-19 minutes | 139 | 129 |
| Established patient office or other outpatient visit, 30-39 minutes | 125 | 121 |
| Established patient office or other outpatient visit, 20-29 minutes | 113 | 104 |
| New patient problem focused exam of visual system | 74 | 74 |
| Extensive repair of turning-outward eyelid defect | 52 | 49 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Erythromycin (erythromycin base) Other prescribers in Kansas City, MO | 748 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Kansas City, MO | 69 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 29 payments worth $11,230 in total to this clinician.
| Amgen Inc. | $11,149 |
|---|---|
| AbbVie Inc. | $33.25 |
| Dompe US, Inc. | $27.61 |
| Glaukos Corporation | $20.39 |
| Compensation for services other than consulting (speaking, faculty) | $9,563 |
|---|---|
| Travel and Lodging | $867 |
| Food and Beverage | $800 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,763 |
| Amgen Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,550 |
| Amgen Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,550 |
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $1,275 |
| Amgen Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $425 |
| Amgen Inc. Mar 8, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX · in-kind | $383 |
| Amgen Inc. Mar 8, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX · in-kind | $304 |
| Amgen Inc. Nov 7, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to Topeka, KS | $91.00 |
| Amgen Inc. Apr 14, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX | $44.00 |
| Amgen Inc. Apr 14, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX | $20.00 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,550 |
| Amgen Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $425 |
| Amgen Inc. Nov 7, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to Topeka, KS | $91.00 |
| Amgen Inc. Nov 7, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to Topeka, KS | $5.48 |
| Amgen Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,550 |
| Amgen Inc. Aug 21, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to Kansas City, MO | $19.60 |
| Amgen Inc. Apr 14, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX | $44.00 |
| Amgen Inc. Apr 14, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX | $20.00 |
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $2,763 |
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEPEZZA · Inflammation/Rare Disease | $1,275 |
| Amgen Inc. Mar 8, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX · in-kind | $383 |
| Amgen Inc. Mar 8, 2025 | Travel and Lodging TEPEZZA · Inflammation/Rare Disease · travel to DALLAS, TX · in-kind | $304 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $25,990 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Durability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC ad…
Argenx US, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.